Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage
Portfolio Pulse from Vandana Singh
The U.S. Centers for Medicare and Medicaid Services has revised its policy to permit multiple uses of amyloid PET scans, a tool for Alzheimer's diagnosis. This change aligns with the eligibility criteria for new Alzheimer's drugs and benefits patients seeking access to such drugs, including Eisai Co Ltd/Biogen Inc's Leqembi and Eli Lilly And Co's experimental drug, donanemab. The policy change also ensures government reimbursement for drugs like Leqembi by confirming the presence of amyloid in the brain.
October 13, 2023 | 7:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The policy change benefits Biogen Inc as it increases the accessibility and potential usage of its Alzheimer's drug, Leqembi.
The policy change allows for multiple uses of amyloid PET scans, which are crucial for diagnosing Alzheimer's and determining treatment eligibility. This could lead to increased usage of Biogen's drug, Leqembi.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
The policy change benefits Eisai Co Ltd as it increases the accessibility and potential usage of its Alzheimer's drug, Leqembi.
The policy change allows for multiple uses of amyloid PET scans, which are crucial for diagnosing Alzheimer's and determining treatment eligibility. This could lead to increased usage of Eisai's drug, Leqembi.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
The policy change benefits Eli Lilly And Co as it increases the accessibility and potential usage of its experimental Alzheimer's drug, donanemab.
The policy change allows for multiple uses of amyloid PET scans, which are crucial for diagnosing Alzheimer's and determining treatment eligibility. This could lead to increased usage of Eli Lilly's experimental drug, donanemab.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80